Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieHumansFerroptosisAmino Acid Transport System y+Lung NeoplasmsProto-Oncogene Proteins p21(ras)
TTP enhances the sensitivity of KRASG12C-mutated lung cancer cells to KRASG12C inhibitors by downregulating SLC7A11 and promoting ferroptosis.
Ki Ra Park, Minh-Xuan Le, Ok Joo Sul, JiHeung Jeon, Min Sung Kwon, Haebin Lee, Seung Won Ra, Hyuk Nam Kwon, Wha Ja Cho, Jeong Woo Park
Published: 202510.1016/j.biopha.2025.118772
Abstract
Covalent KRASG12C inhibitors are used to treat patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). However, many patients do not respond to therapy due to intrinsic or acquired resistance. The mechanisms underlying resistance to KRASG1…
Preview only. Read the full abstract at the source